Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.61 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6434881 | 0.87 | SIGMAR1 (0.57) | SIGMAR1PARP1HTR1AKCNA3 | |
| SCHEMBL6367491 | 0.84 | SIGMAR1 (0.44) | SIGMAR1PPARGPPARAKCNA3 | |
| SCHEMBL18936739 | 0.84 | SIGMAR1 (0.66) | SIGMAR1PARP1PPARGPPARAMEN1 | |
| SCHEMBL6368539 | 0.83 | KCNA3 (0.57) | SIGMAR1PARP1HTR1AKCNA3 | |
| SCHEMBL5536604 | 0.83 | SIGMAR1 (0.65) | SIGMAR1PARP1PPARGPPARAMEN1 | |
| SCHEMBL6373059 | 0.83 | SIGMAR1 (0.61) | SIGMAR1PARP1PPARGPPARAHTR1A | |
| SCHEMBL6372796 | 0.83 | SIGMAR1 (0.58) | SIGMAR1PARP1MEN1KMT2AKCNA3 | |
| SCHEMBL6372804 | 0.82 | KCNA3 (0.60) | SIGMAR1HTR1AKCNA3 | |
| SCHEMBL5541688 | 0.82 | SIGMAR1 (0.67) | SIGMAR1PARP1PPARGPPARAMEN1 | |
| SCHEMBL5539408 | 0.81 | SIGMAR1 (0.62) | SIGMAR1PARP1PPARGPPARAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | PARP1, PARP2, PARP3 | SIGMAR1 3797/4885PARP1 1/4885PPARG 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.